oclacitinib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND Ciclosporin and oclacitinib are immunomodulators approved for the treatment of canine atopic dermatitis. The… (More)
Is this relevant?
2015
2015
The prevalence of allergic skin disorders has increased rapidly, and development of therapeutic agents to alleviate the symptoms… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
BACKGROUND Oclacitinib is a Janus kinase inhibitor that decreases pruritus and lesions in allergic dogs. In cats, it is able to… (More)
Is this relevant?
2015
2015
BACKGROUND Ciclosporin is approved for the treatment of atopic dermatitis (AD) in dogs and has been shown to be safe and… (More)
  • table 1
  • table 2
  • figure 1
  • table 4
  • figure 2
Is this relevant?
2015
2015
Janus kinase (JAK) inhibitors have recently been developed for allergic diseases. We focused on the 2 different JAK inhibitors… (More)
Is this relevant?
2015
2015
BACKGROUND In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of… (More)
  • table 1
Is this relevant?
2014
2014
Janus kinase (JAK) enzymes are involved in cell signaling pathways activated by various cytokines dysregulated in allergy. The… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2014
2014
BACKGROUND Oral glucocorticoids are widely used to reduce pruritus and dermatitis associated with allergic dermatitis. Data… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2013
2013
BACKGROUND Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Preliminary study results suggest that… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2013
2013
BACKGROUND Oclacitinib (Apoquel(®) ) inhibits the function of a variety of pro-inflammatory, pro-allergic and pruritogenic… (More)
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?